Last updated: September 25, 2026
Flovent Diskus 100 is the 100 mcg strength of fluticasone propionate inhalation powder, a twice-daily inhaled corticosteroid used for maintenance treatment of asthma. Its commercial trajectory has shifted from branded growth to mature-product erosion. In the United States, GSK ended direct sales of Flovent HFA and Flovent Diskus after 2023 and transferred commercial supply to an authorized-generic model. The 100 mcg presentation remains clinically relevant, but its financial value is now tied to generic pricing, formulary access, supply reliability, and residual device and formulation barriers rather than brand expansion.
GSK does not publicly report revenue for Flovent Diskus 100 separately. Reported financial figures generally combine Flovent strengths, inhaler formats, geographies, and sometimes the broader respiratory portfolio. Any valuation that assigns a precise standalone revenue figure to the 100 mcg strength is therefore an estimate, not a company-reported result.
What is Flovent Diskus 100 and how does it compete?
Flovent Diskus 100 contains 100 mcg of fluticasone propionate per inhalation. The Diskus is a multi-dose dry-powder inhaler. The product is designed for regular controller therapy and is not a rescue inhaler for acute bronchospasm.
| Attribute |
Product detail |
| Active ingredient |
Fluticasone propionate |
| Dosage form |
Dry-powder inhalation |
| Strength |
100 mcg per blister dose |
| Original company |
GlaxoSmithKline |
| U.S. regulatory application |
NDA 020833 family |
| Primary indication |
Maintenance treatment of asthma |
| Typical positioning |
Inhaled corticosteroid monotherapy |
| Rescue role |
None |
| Main substitutes |
Generic fluticasone propionate inhalation powder, Arnuity Ellipta, Pulmicort Flexhaler, QVAR RediHaler, inhaled corticosteroid/long-acting bronchodilator products |
Flovent Diskus 100 competes in a crowded inhaled-corticosteroid market. Its principal advantages were physician familiarity, long clinical history, established payer contracts, and a well-known dose-counter device. Its disadvantages are the absence of a long-acting bronchodilator, twice-daily administration, and increasing price pressure from generic and authorized-generic alternatives.
When did Flovent Diskus lose exclusivity?
Flovent Diskus lost the commercial characteristics of a protected branded product well before GSK’s U.S. withdrawal. The product had been marketed for decades, and the main active-ingredient and product patents had reached or passed their ordinary expiration periods before the 2024 authorized-generic transition.
The practical loss of exclusivity occurred in stages:
| Period |
Market event |
Commercial effect |
| 1990s |
FDA approval and brand launch of Flovent products |
Establishment of fluticasone propionate as a major inhaled corticosteroid |
| 2000s |
Expansion across strengths and inhaler formats |
Broad physician and payer adoption |
| 2010s |
Mature-product pricing and substitution pressure |
Slower growth and declining strategic priority |
| 2022-2023 |
Generic and authorized-generic preparations |
Increased risk of price erosion |
| January 2024 |
GSK discontinued U.S. Flovent HFA and Diskus sales |
Brand revenue converted into generic or authorized-generic economics |
The end of brand sales did not mean immediate disappearance from the market. Prasco marketed an authorized generic based on the FDA-approved Flovent products. Authorized generics generally preserve the reference product’s formulation and device identity while reducing the brand premium.
What is the Orange Book status of Flovent Diskus 100?
Flovent Diskus is associated with GSK’s Flovent NDA record in the FDA’s Drugs@FDA database and Orange Book framework. The Orange Book is relevant for identifying listed patents, regulatory exclusivity, and generic-approval pathways, but it does not establish a single expiration date for every commercial barrier.
The product’s protection historically involved several layers:
- Fluticasone propionate composition and pharmaceutical patents.
- Dry-powder inhaler and blister-packaging patents.
- Device patents covering the Diskus inhaler.
- Manufacturing and particle-engineering know-how.
- Regulatory and clinical information supporting the reference product.
The active-ingredient and core product protections are no longer the principal commercial barrier. The more relevant remaining barriers are device replication, inhalation-performance testing, manufacturing consistency, and payer-channel access.
A patent expiry date should not be interpreted as a guaranteed generic launch date. Inhaled products require comparative aerodynamic particle-size distribution, emitted-dose testing, dose-content uniformity, device performance testing, and clinical or pharmacodynamic support under the applicable FDA pathway.
Which companies have challenged or replaced Flovent Diskus?
The competitive threat comes from both direct fluticasone products and therapeutic substitutes.
Generic and authorized-generic competition
The authorized generic associated with Prasco is the most direct replacement for the branded U.S. product. It is commercially important because it can use the established Flovent product platform while being sold at a lower price.
Generic applicants for inhaled corticosteroids have historically faced greater technical hurdles than applicants for conventional tablets. The relevant competition is not limited to the active ingredient. It includes:
- Powder particle size and morphology.
- Blister filling and moisture control.
- Device airflow resistance.
- Dose delivery across inhalation rates.
- Consistency near the end of the labeled device life.
- Comparative in vitro and, where required, clinical performance.
Publicly reported generic activity around fluticasone inhalation products has included companies such as Hikma, Teva, and other respiratory-generic manufacturers across different product formats and combinations. The competitive set must be assessed by exact product, device, strength, and FDA approval status. Generic fluticasone propionate products are not interchangeable merely because they contain the same active ingredient.
Therapeutic substitutes
Flovent Diskus 100 also competes with products that do not replicate its device:
| Product |
Ingredient or class |
Competitive relevance |
| Arnuity Ellipta |
Fluticasone furoate |
Same broad corticosteroid class; once-daily positioning |
| Pulmicort Flexhaler |
Budesonide |
Established inhaled corticosteroid alternative |
| QVAR RediHaler |
Beclomethasone dipropionate |
Breath-actuated alternative |
| Alvesco |
Ciclesonide |
Inhaled corticosteroid alternative |
| Advair/Wixela |
Fluticasone propionate plus salmeterol |
Combination therapy; competes when bronchodilator treatment is required |
| Symbicort and generic budesonide/formoterol |
Inhaled corticosteroid plus long-acting bronchodilator |
Major step-up therapy alternative |
The competitive threat is therefore broader than a one-for-one generic. Physicians may switch patients to another corticosteroid, a once-daily device, or a combination inhaler depending on disease severity and payer rules.
What is the financial trajectory for Flovent Diskus 100?
The financial trajectory is declining in branded terms and structurally lower-margin in generic terms.
GSK’s respiratory franchise historically generated substantial revenue from products including Flovent, Advair, Breo, Anoro, and Trelegy. Flovent was an important mature respiratory brand, but GSK did not disclose separate revenue for Flovent Diskus 100. The company’s financial reporting also does not isolate U.S. Diskus revenue from HFA revenue or distinguish the 100 mcg strength from the 250 mcg and 500 mcg strengths.
Revenue phases
| Phase |
Revenue profile |
Margin profile |
| Brand expansion |
Increasing prescriptions and broad formulary access |
High branded gross margin |
| Mature brand |
Stable or declining volume with price pressure |
Still attractive but deteriorating |
| Generic transition |
Rapid loss of brand price premium |
Lower margin and higher channel pressure |
| Authorized-generic phase |
Retained manufacturing or supply economics without full brand pricing |
Moderate to low relative margin |
| Long-term mature market |
Volume dependent on contracts and supply reliability |
Commodity-like economics |
The key financial event was the U.S. transition away from direct Flovent sales. GSK retained a route to market through an authorized generic, but this model generally captures less value per prescription than a branded product. The extent of retained economics depends on transfer pricing, manufacturing arrangements, distributor terms, and the degree of competition from independent ANDA products.
How did GSK’s Flovent withdrawal change the market?
GSK’s decision affected three market segments:
- Patients and physicians had to manage a product-name transition.
- Pharmacies and payers had to update reimbursement and preferred-product rules.
- GSK shifted the product from a branded franchise model to a lower-cost supply model.
The change reduced the risk of an abrupt product shortage because the authorized generic was intended to maintain access to the same underlying product. It also reduced the probability that GSK would continue bearing the full commercial cost of supporting a mature brand with declining pricing power.
The transition created several operational risks:
- Temporary pharmacy confusion between brand and authorized generic.
- Formulary delays.
- Prescription rejection caused by National Drug Code changes.
- Differences in patient co-pay treatment.
- Competition from products using different inhaler devices.
- Inventory fluctuations during channel conversion.
What patent litigation and Paragraph IV risks affect Flovent Diskus?
The central Paragraph IV risk for Flovent Diskus is technical rather than purely chemical. A generic applicant must address listed patents and demonstrate that its inhaler delivers a therapeutically comparable dose. The relevant litigation questions include:
- Whether a listed device or formulation patent remains enforceable.
- Whether the proposed generic uses a non-infringing inhaler architecture.
- Whether the applicant’s certification triggers a 30-month stay.
- Whether the applicant secures a first-filer position.
- Whether the applicant settles before commercial launch.
- Whether the FDA approves the product after patent barriers expire or are resolved.
The market risk from a Paragraph IV filing depends on the exact strength and device. A challenge to Flovent Diskus 100 does not automatically authorize a generic for Flovent HFA or a different fluticasone strength.
No biosimilar risk applies. Fluticasone propionate is a chemically synthesized small molecule, not a biologic. The applicable route is an ANDA or another small-molecule pathway, not a biosimilar application under the Public Health Service Act.
What formulation and manufacturing barriers protect Flovent Diskus?
The most durable non-patent barriers are manufacturing controls and device-performance requirements.
Formulation barriers
Fluticasone propionate is delivered as a finely engineered dry powder. Commercial performance depends on:
- Active-particle size.
- Carrier-particle interaction.
- Powder flow.
- Moisture sensitivity.
- Blending uniformity.
- De-agglomeration during inhalation.
- Delivered dose across patient inhalation profiles.
These variables can create meaningful development costs even after composition patents expire.
Device barriers
The Diskus platform uses pre-metered blister doses and a mechanical loading and dose-delivery system. A competing manufacturer can replicate the therapeutic product without using the identical device, but it must demonstrate reliable dose delivery and acceptable patient use characteristics.
The device is commercially valuable because switching inhalers can affect adherence, inhalation technique, patient training, and payer acceptance. Device familiarity therefore supports residual market share even after patent expiry.
How does Flovent Diskus 100 compare with Arnuity Ellipta and Pulmicort Flexhaler?
| Factor |
Flovent Diskus 100 |
Arnuity Ellipta |
Pulmicort Flexhaler |
| Active ingredient |
Fluticasone propionate |
Fluticasone furoate |
Budesonide |
| Device |
Diskus dry-powder inhaler |
Ellipta dry-powder inhaler |
Flexhaler |
| Dosing profile |
Typically twice daily |
Once daily |
Typically twice daily |
| Brand status |
U.S. brand withdrawn from direct sales |
Active branded product |
Active branded product |
| Generic pressure |
High |
Lower than Flovent at the time of transition |
Generic and competitive pressure |
| Main advantage |
Familiar product and device |
Once-daily convenience |
Broad clinical familiarity |
| Main weakness |
Mature product and pricing erosion |
Brand price and formulary restrictions |
Device and dosing competition |
Flovent’s strongest remaining advantage is familiarity. Its main weakness is that a mature twice-daily monotherapy faces both direct generic competition and newer once-daily or combination products.
What generic launch scenarios exist for Flovent Diskus 100?
Three scenarios define the likely market outcome.
Authorized-generic dominance
The Prasco-linked authorized generic retains most prescriptions because physicians and pharmacies treat it as the closest replacement for Flovent Diskus. Price erosion is present but controlled. This scenario protects a meaningful portion of the installed base.
Multi-generic competition
Independent ANDA approvals create several suppliers. Prices decline more rapidly, and pharmacy benefit managers use preferred formulary placement to force substitution. Manufacturing reliability becomes a major determinant of share.
Therapeutic substitution
Payers steer patients toward generic budesonide, Arnuity Ellipta, QVAR, or inhaled corticosteroid/long-acting bronchodilator products. Flovent Diskus volume declines even if direct generic competition remains limited.
The third scenario is particularly relevant for the 100 mcg strength because asthma treatment often changes with disease severity. A patient may move from inhaled corticosteroid monotherapy to a combination inhaler rather than remain within the fluticasone propionate product family.
What is the geographic coverage and revenue exposure?
Flovent’s commercial exposure was historically international, but product names, devices, approvals, patent positions, and reimbursement rules vary by country. U.S. exposure is strategically important because the U.S. has higher inhaler prices and stronger generic substitution incentives than many other markets.
Revenue exposure is concentrated in the mature-brand phase:
- U.S. brand revenue has been materially impaired by the post-2023 withdrawal.
- Authorized-generic revenue may preserve supply-related economics.
- International sales depend on local registrations and generic competition.
- The 100 mcg strength is more exposed to first-line asthma substitution than higher strengths used in more severe disease.
- Portfolio value is lower than the product’s historical revenue because GSK’s respiratory growth is concentrated in newer products such as Trelegy.
How strong is the remaining patent estate for Flovent Diskus 100?
The remaining estate is commercially moderate but no longer brand-defining. Core pharmaceutical exclusivity has expired or ceased to provide a meaningful standalone barrier. Device and formulation patents may still affect specific generic designs, but they do not recreate the original branded moat.
Patent strength should be assessed on four dimensions:
| Dimension |
Current assessment |
| Composition protection |
Weak as a commercial barrier |
| Device protection |
Potentially relevant to exact Diskus replication |
| Formulation protection |
Relevant where claims cover powder engineering or delivery performance |
| Manufacturing know-how |
Potentially durable and difficult to replicate |
The commercial risk is therefore driven less by whether a competitor can enter the fluticasone market and more by how quickly it can achieve FDA approval, stable manufacturing, pharmacy distribution, and favorable formulary status.
Key Takeaways
- Flovent Diskus 100 is a mature fluticasone propionate dry-powder inhaler.
- GSK ended direct U.S. brand sales after 2023 and moved the product into an authorized-generic model.
- GSK does not disclose revenue for the 100 mcg strength separately.
- The product’s financial trajectory is downward in branded terms and lower-margin in generic terms.
- Patent expiry is no longer the primary commercial issue; device replication, powder engineering, FDA approval, and payer access are more important.
- The product faces direct generic competition from fluticasone products and indirect competition from budesonide, fluticasone furoate, beclomethasone, and combination inhalers.
- No biosimilar pathway applies because fluticasone propionate is a small-molecule drug.
- The most likely long-term outcome is continued prescription erosion, with residual volume determined by authorized-generic availability, formulary placement, and patient familiarity with the Diskus device.
FAQs
Is Flovent Diskus 100 still available in the United States?
The branded product was discontinued from direct U.S. sales after 2023. An authorized-generic version was introduced to preserve access to the underlying product.
Is Flovent Diskus 100 the same as generic fluticasone propionate?
An authorized generic is based on the approved Flovent product. An independent generic may use a different device or manufacturing platform and must satisfy FDA requirements for its specific product.
Does Flovent Diskus 100 have a biosimilar competitor?
No. Fluticasone propionate is a small molecule, so competitors use the generic-drug approval pathway rather than the biosimilar pathway.
Which product is the closest alternative to Flovent Diskus 100?
The closest product is a fluticasone propionate inhalation-powder product using a comparable delivery system. Arnuity Ellipta, Pulmicort Flexhaler, and QVAR RediHaler are therapeutic alternatives but are not identical products.
Why can inhaler generics launch slowly after patent expiry?
Inhaler generics require complex comparative testing for dose delivery, particle size, device performance, powder uniformity, and patient-use characteristics. These requirements can delay approval and limit the number of commercially viable suppliers.
References
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Flovent Diskus, NDA 020833. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
U.S. Food and Drug Administration. (2023). Flovent Diskus prescribing information. GlaxoSmithKline.
-
GSK plc. (2024). Annual report 2023. https://www.gsk.com/en-gb/investors/
-
GSK plc. (2023, December 19). GSK provides update on U.S. Flovent access. Corporate announcement.
-
U.S. Food and Drug Administration. (2023). Product-specific guidance for fluticasone propionate inhalation powder. https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs-supplied-inhalation-devices-industry-part-3.
